Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™)
Sponsor: Boston Scientific Corporation
A PHASE3 clinical study on Myocardial Infarction, this trial is completed. The trial is conducted by Boston Scientific Corporation and has accumulated 7 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
- Cardiovascular Research Foundation, New York
- The Medicines Company
For direct contact, visit the study record on ClinicalTrials.gov .